GlassScriptPhysician profile
Ramachandra U Hosmane
NPI 1255481362
$777.93
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $42.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $197.92 | 2019 | |
| Astellas Pharma US INC | $173.92 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.30 | 2019 | |
| Abbott Laboratories | $124.35 | 2019 | |
| Janssen Biotech, INC. | $41.90 | 2019 | |
| Boston Scientific Corporation | $30.56 | 2019-2020 | |
| Amgen INC. | $27.33 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $15.20 | 2019 | |
| Neotract INC. | $12.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramachandra Hosmane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.